Lehua Li
China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.
Journal: Therapeutic advances in psychopharmacology
Published: February 02, 2023
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.
Journal: Translational psychiatry
Published: October 18, 2022
A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder.
Journal: Journal of affective disorders
Published: August 02, 2022
Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial.
Journal: The international journal of neuropsychopharmacology
Published: August 11, 2021
Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia.
Journal: Psychiatry and clinical neurosciences
Published: July 01, 2019
Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study.
Journal: Frontiers in neuroscience
Published: May 04, 2019
Central and Peripheral Changes in FOS Expression in Schizophrenia Based on Genome-Wide Gene Expression.
Journal: Frontiers in genetics
Published: October 24, 2018
Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model.
Journal: Frontiers in neurology
Published: October 15, 2017
Treatment effects of olanzapine on homotopic connectivity in drug-free schizophrenia at rest.
Journal: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
Published: June 27, 2017
Olanzapine modulates the default-mode network homogeneity in recurrent drug-free schizophrenia at rest.
Journal: The Australian and New Zealand journal of psychiatry
Published: June 14, 2017
Hyperactivity of the default-mode network in first-episode, drug-naive schizophrenia at rest revealed by family-based case-control and traditional case-control designs.
Journal: Medicine
Published: March 30, 2017
Anatomical distance affects cortical-subcortical connectivity in first-episode, drug-naive somatization disorder.
Journal: Journal of affective disorders
Published: January 19, 2017
Last Updated: 09/26/2026